SALT LAKE CITY, July 14, 2025 /PRNewswire/ — Supplemental Health Care (SHC), a national leader in workforce solutions, is proud to announce the release of its Technology with Purpose Report 2025. This comprehensive report highlights how SHC is leveraging advanced artificial intelligence (AI) tools and customer-centric strategies to redefine healthcare workforce solutions, enhance candidate engagement, and deliver exceptional client experiences.
SHC’s release of this new report shows the company’s continued commitment to integrating cutting-edge technology with its four decades of industry knowledge. Chief Digital Officer, Simon Curtis shared that in addition to SHC’s tools and expertise, “we can ensure that exciting innovation is also supported by personal relationships and human connection, which we believe will allow us to continue delivering exceptional experiences for all of our partners across the workforce solutions landscape.”
The report highlights key milestones and achievements, showcasing SHC’s utilization of technology and AI tools as well as its internal leadership and industry expertise:
Supplemental Health Care is committed to further integrating AI into workforce solutions, enhancing self-service tools, and providing transparent job search support. With a focus on combining empathy with innovation, SHC aims to put its patients, providers, and partners at the heart of care delivery across behavioral health, education, and healthcare services.
About Supplemental Health Care
Supplemental Health Care (SHC) is a leading behavioral health, education, and healthcare workforce solutions provider that connects caring nurses, therapists, and other healthcare professionals with opportunities to fulfill their calling to better serve patients and students. SHC is proud to deliver world-class service and career options to our clinicians, a range of dynamic workforce solutions to our clients, and a supportive atmosphere to our corporate teams. For everyone that we serve, SHC is the place where caring hearts thrive.
Media Contact:
Alex Acton
770-225-8453
SOURCE Supplemental Health Care
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…